<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168295</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160042H</org_study_id>
    <secondary_id>R01DK107680</secondary_id>
    <nct_id>NCT03168295</nct_id>
  </id_info>
  <brief_title>PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria</brief_title>
  <official_title>SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose/Objectives: Examining the effect of SGLT2 inhibition on EGP and plasma glucose
      concentration in diabetic and non-diabetic subjects after kidney transplantation (i.e. renal
      denervation) or in subjects after renal sympathectomy (63) can add insight about the possible
      role of a neural arc which mediates the changes in plasma glucagon and/or insulin
      concentration in response to glucosuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose/Objectives: Examining the effect of SGLT2 inhibition on EGP and plasma glucose
      concentration in diabetic and non-diabetic subjects after kidney transplantation (i.e. renal
      denervation) or in subjects after renal sympathectomy (63) can add insight about the possible
      role of a neural arc which mediates the changes in plasma glucagon and/or insulin
      concentration in response to glucosuria.

      Research Design/Plan: After screening, eligible subjects will receive 2 measurements of
      endogenous glucose production with a prime-continuous infusion of 3-3H-glucose. Each
      measurement will be performed on a separate day in random order after a 10-12 hour overnight
      fast and will last 8 hours (from 6 AM to 2 PM). After a 3-hour tracer equilibration period,
      each subject will receive one of the following medications in random order: (i) placebo and
      (ii) dapagliflozin 10 mg. Following the test medication at 9 AM, blood samples will be drawn
      every 20 minutes for an additional 5 hours and plasma glucose, insulin, C-peptide, glucagon,
      catecholamine concentrations and tritiated glucose sp act will be measured.

      Methods: Visit 1: Screening Visit 2: Endogenous Glucose Production Measurement (EGP) Visit 3:
      After completing the first EGP measurement, subjects will return to the Diabetes Research
      Unit for the second study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Post renal transplant type 2 diabetes mellitus patients and non-diabetic mellitus patients after renal transplant with a control group of type 2 diabetes mellitus who have not undergone renal transplant</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous Glucose Production (EGP)</measure>
    <time_frame>baseline and 240-300 minutes</time_frame>
    <description>Renal transplant subjects with native kidneys intact underwent measurement of EGP with an 8 hour infusion of 3-3H-glucose on 2 separate days with the administration in random order of either dapagliflozin 10mg or placebo after 3 hours of the tracer equilibration period. The equilibration at 3 hours was considered the baseline measurement. Measurement of change in endogenous glucose production was obtained for all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>baseline and 240-300 minutes</time_frame>
    <description>Change in Fasting Plasma Glucose in Type 2 Diabetes Mellitus subjects only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Insulin</measure>
    <time_frame>baseline and 240-300 minutes</time_frame>
    <description>Change in Fasting Plasma Insulin in Type 2 Diabetes Mellitus subjects in diabetic subjects only</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo first and then dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin first then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg then Placebo Oral Tablet</intervention_name>
    <description>SGLT2 inhibitor - Dapagliflozin then Placebo</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Dapagliflozin first then placebo</arm_group_label>
    <arm_group_label>Placebo first and then dapagliflozin</arm_group_label>
    <other_name>Farxiga then placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet then Dapagliflozin 10mg</intervention_name>
    <description>Placebo then SGLT2 inhibitor - Dapagliflozin</description>
    <arm_group_label>Dapagliflozin first then placebo</arm_group_label>
    <arm_group_label>Placebo first and then dapagliflozin</arm_group_label>
    <other_name>Placebo then Farxiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age = 18-70 years

          -  BMI = 18.5-40 kg/m2

          -  HbA1c ≥ 7.0% and ≤10.0% for type 2 diabetics

          -  males or females

          -  Must be at least 3 months post renal transplantation and be on a stable dose of
             prednisone (≤5 mg/day), tacrolimus, and mycophenolate mofetil

          -  Not taking any antidiabetic medications or who are treated with metformin,
             sulfonylurea, dipeptidyl peptidase 4 (DPP4) inhibitor, thiazolidinedione or some
             combination

          -  Must be in good general health as determined by physical exam, medical history, blood
             chemistries, CBC, TSH, T4, EKG and urinanalysis

        Exclusion Criteria:

          -  Subjects who are taking insulin or SGLT2 inhibitor are excluded

          -  Only subjects whose body weight has not been stable (± 3 lbs) over the preceding three
             months and/or who participate in an excessively heavy exercise program will be
             excluded.

          -  Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine
             &gt;1.4 females or &gt;1.5 males (and eGFR &lt;45ml/min.1.73m2), or 24-hour urine albumin
             excretion &gt; 300 mg will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>December 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03168295/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Diabetic and non-diabetic subjects were assigned to both interventions after randomization, either dapagliflozin first with placebo second, or placebo first and then dapagliflozin next.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin First - Diabetic</title>
          <description>Subjects who have undergone renal transplant are randomly assigned to receive either dapagliflozin first followed by the placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Tablet First - Diabetic</title>
          <description>Subjects who have undergone renal transplant are randomly assigned to receive placebo first followed by dapagliflozin</description>
        </group>
        <group group_id="P3">
          <title>Dapagliflozin First - Non-diabetic</title>
          <description>Non-diabetic subjects who have undergone renal transplant are randomly assigned to dapagliflozin first and then receive placebo</description>
        </group>
        <group group_id="P4">
          <title>Placebo Oral Tablet First - Non-diabetic</title>
          <description>Non-diabetic subjects who have undergone renal transplant are randomly assigned to placebo first and then receive dapagliflozin</description>
        </group>
        <group group_id="P5">
          <title>Control Group</title>
          <description>Type 2 Diabetic subjects who did not undergo renal transplant and received dapagliflozin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who underwent renal transplant surgery with intact native kidneys, and a type 2 diabetic control group that did not undergo renal transplant</population>
      <group_list>
        <group group_id="B1">
          <title>Diabetic Subjects</title>
          <description>Diabetic renal transplant subjects with native kidneys intact who were Type 2 diabetics</description>
        </group>
        <group group_id="B2">
          <title>Non-diabetic Subjects</title>
          <description>Non-diabetic subjects after renal transplant with intact native kidneys</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Type 2 diabetic subjects who did not under go renal transplant</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Subjects between 18 and 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>6 of the subjects analyzed were diabetic and the remaining 8 were non-diabetic</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1C (average blood glucose level over 3 months)</title>
          <units>Percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="0.1"/>
                    <measurement group_id="B2" value="5.6" spread="0.1"/>
                    <measurement group_id="B3" value="7.5" spread="0.2"/>
                    <measurement group_id="B4" value="6.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Endogenous Glucose Production (EGP)</title>
        <description>Renal transplant subjects with native kidneys intact underwent measurement of EGP with an 8 hour infusion of 3-3H-glucose on 2 separate days with the administration in random order of either dapagliflozin 10mg or placebo after 3 hours of the tracer equilibration period. The equilibration at 3 hours was considered the baseline measurement. Measurement of change in endogenous glucose production was obtained for all subjects.</description>
        <time_frame>baseline and 240-300 minutes</time_frame>
        <population>The control group did not have renal surgery and were only administered the dapagliflozin, not the placebo, so no participants show for baseline or 240 to 300 minutes for placebo measurements, only for dapagliflozin.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic Subjects</title>
            <description>Renal transplant subjects with native kidneys intact who were Type 2 diabetics</description>
          </group>
          <group group_id="O2">
            <title>Non-diabetic Subjects</title>
            <description>Non-diabetic subjects after renal transplant with intact native kidneys</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Type 2 diabetic subjects who did not undergo renal surgery and received dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endogenous Glucose Production (EGP)</title>
          <description>Renal transplant subjects with native kidneys intact underwent measurement of EGP with an 8 hour infusion of 3-3H-glucose on 2 separate days with the administration in random order of either dapagliflozin 10mg or placebo after 3 hours of the tracer equilibration period. The equilibration at 3 hours was considered the baseline measurement. Measurement of change in endogenous glucose production was obtained for all subjects.</description>
          <population>The control group did not have renal surgery and were only administered the dapagliflozin, not the placebo, so no participants show for baseline or 240 to 300 minutes for placebo measurements, only for dapagliflozin.</population>
          <units>mg/kg.min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.20"/>
                    <measurement group_id="O2" value="1.92" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.09"/>
                    <measurement group_id="O2" value="1.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.19"/>
                    <measurement group_id="O2" value="1.85" spread="0.10"/>
                    <measurement group_id="O3" value="2.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.14"/>
                    <measurement group_id="O2" value="1.78" spread="0.10"/>
                    <measurement group_id="O3" value="2.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose</title>
        <description>Change in Fasting Plasma Glucose in Type 2 Diabetes Mellitus subjects only</description>
        <time_frame>baseline and 240-300 minutes</time_frame>
        <population>Only type 2 diabetic subjects were included in this group, so the 8 non-diabetic renal transplant subjects were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic Subjects</title>
            <description>Renal transplant subjects with native kidneys intact who were Type 2 diabetics</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects who are type 2 diabetics who did not undergo renal transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose</title>
          <description>Change in Fasting Plasma Glucose in Type 2 Diabetes Mellitus subjects only</description>
          <population>Only type 2 diabetic subjects were included in this group, so the 8 non-diabetic renal transplant subjects were not included.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="15"/>
                    <measurement group_id="O2" value="135.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="9"/>
                    <measurement group_id="O2" value="106.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Insulin</title>
        <description>Change in Fasting Plasma Insulin in Type 2 Diabetes Mellitus subjects in diabetic subjects only</description>
        <time_frame>baseline and 240-300 minutes</time_frame>
        <population>Only type 2 diabetic subjects were included in this group, so the 8 subjects who were non-diabetic who had renal transplant were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic Subjects</title>
            <description>Renal transplant subjects with native kidneys intact who were Type 2 diabetics</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects who are type 2 diabetics who did not undergo renal transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Insulin</title>
          <description>Change in Fasting Plasma Insulin in Type 2 Diabetes Mellitus subjects in diabetic subjects only</description>
          <population>Only type 2 diabetic subjects were included in this group, so the 8 subjects who were non-diabetic who had renal transplant were not included.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="3"/>
                    <measurement group_id="O2" value="15.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240-300 minute measurement Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2"/>
                    <measurement group_id="O2" value="9.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 8 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diabetic Subjects Dapagliflozin</title>
          <description>Diabetic subjects who have undergone kidney surgery, and have a dapagliflozin infusion</description>
        </group>
        <group group_id="E2">
          <title>Diabetic Subjects Placebo</title>
          <description>Diabetic subjects who have undergone kidney surgery, and have a placebo infusion</description>
        </group>
        <group group_id="E3">
          <title>Non-diabetic Subjects Dapagliflozin</title>
          <description>Non-Diabetic subjects who have undergone kidney surgery, and have a dapagliflozin infusion</description>
        </group>
        <group group_id="E4">
          <title>Non-diabetic Subjects Placebo</title>
          <description>Non-Diabetic subjects who have undergone kidney surgery, and have a placebo infusion</description>
        </group>
        <group group_id="E5">
          <title>Control Group</title>
          <description>Type 2 Diabetic subjects who have not undergone renal surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carolina Solis-Herrera</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>(210) 567-6691</phone>
      <email>solisherrera@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

